-$0.58 Earnings Per Share Expected for Dynavax Technologies Co. (DVAX) This Quarter

Equities research analysts predict that Dynavax Technologies Co. (NASDAQ:DVAX) will report earnings per share of ($0.58) for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for Dynavax Technologies’ earnings, with the highest EPS estimate coming in at ($0.56) and the lowest estimate coming in at ($0.60). Dynavax Technologies posted earnings of ($0.38) per share during the same quarter last year, which would indicate a negative year over year growth rate of 52.6%. The business is scheduled to announce its next earnings report on Friday, November 2nd.

On average, analysts expect that Dynavax Technologies will report full-year earnings of ($2.39) per share for the current financial year, with EPS estimates ranging from ($2.42) to ($2.33). For the next year, analysts forecast that the firm will post earnings of ($1.46) per share, with EPS estimates ranging from ($1.70) to ($1.23). Zacks’ EPS averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Dynavax Technologies.

Dynavax Technologies (NASDAQ:DVAX) last posted its quarterly earnings results on Monday, August 6th. The biopharmaceutical company reported ($0.63) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.62) by ($0.01). Dynavax Technologies had a negative net margin of 8,570.06% and a negative return on equity of 72.31%. The company had revenue of $1.25 million for the quarter, compared to the consensus estimate of $1.88 million. During the same period in the prior year, the firm posted ($0.41) EPS. The business’s revenue was up 1094.3% on a year-over-year basis.

A number of equities analysts recently commented on DVAX shares. BidaskClub raised shares of Dynavax Technologies from a “sell” rating to a “hold” rating in a research note on Saturday, June 16th. Cantor Fitzgerald set a $27.00 price objective on shares of Dynavax Technologies and gave the stock a “buy” rating in a research note on Monday, June 4th. ValuEngine raised shares of Dynavax Technologies from a “hold” rating to a “buy” rating in a research note on Saturday, June 2nd. Finally, Zacks Investment Research raised shares of Dynavax Technologies from a “sell” rating to a “hold” rating in a research note on Tuesday, July 24th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the stock. Dynavax Technologies currently has an average rating of “Hold” and a consensus target price of $27.50.

A number of large investors have recently modified their holdings of the stock. Northern Trust Corp grew its holdings in Dynavax Technologies by 9.8% in the second quarter. Northern Trust Corp now owns 750,442 shares of the biopharmaceutical company’s stock worth $11,445,000 after purchasing an additional 66,677 shares during the last quarter. Bain Capital Public Equity Management LLC purchased a new position in Dynavax Technologies in the second quarter worth $4,198,000. Millennium Management LLC grew its holdings in Dynavax Technologies by 184.6% in the second quarter. Millennium Management LLC now owns 129,902 shares of the biopharmaceutical company’s stock worth $1,981,000 after purchasing an additional 84,254 shares during the last quarter. PointState Capital LP purchased a new position in Dynavax Technologies in the second quarter worth $28,800,000. Finally, First Light Asset Management LLC grew its holdings in Dynavax Technologies by 21.0% in the second quarter. First Light Asset Management LLC now owns 548,777 shares of the biopharmaceutical company’s stock worth $8,369,000 after purchasing an additional 95,143 shares during the last quarter. 82.02% of the stock is owned by institutional investors.

Shares of Dynavax Technologies stock traded down $0.30 on Thursday, hitting $12.10. 585,800 shares of the company traded hands, compared to its average volume of 1,358,197. The company has a debt-to-equity ratio of 0.76, a quick ratio of 8.67 and a current ratio of 8.87. Dynavax Technologies has a 52 week low of $11.35 and a 52 week high of $24.45. The company has a market capitalization of $776.43 million, a PE ratio of -7.08 and a beta of 0.24.

About Dynavax Technologies

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. The company's lead product candidates include HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of the virus in adults age 18 years and older; SD-101, a cancer immunotherapy that is in Phase 2 clinical studies; and DV281, an investigational TLR9 agonist for the treatment of non-small cell lung cancer.

Read More: Why is the conference call important?

Get a free copy of the Zacks research report on Dynavax Technologies (DVAX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Dynavax Technologies (NASDAQ:DVAX)

Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply